1. Li, Zhipeng, Zhou, Huaxin, Zhai, Xiangyu, Wang, Wei, Jin, Bin. 2023. MELK promotes HCC carcinogenesis through modulating cuproptosis-related gene DLAT-mediated mitochondrial function. In Cell death & disease, 14, 733. doi:10.1038/s41419-023-06264-3. https://pubmed.ncbi.nlm.nih.gov/37949877/
2. Li, Zhipeng, Zhou, Huaxin, Zhai, Xiangyu, Wang, Wei, Jin, Bin. 2023. Correction: MELK promotes HCC carcinogenesis through modulating cuproptosis-related gene DLAT-mediated mitochondrial function. In Cell death & disease, 14, 840. doi:10.1038/s41419-023-06367-x. https://pubmed.ncbi.nlm.nih.gov/38110350/
3. Tang, Bufu, Zhu, Jinyu, Shi, Yueli, Chen, Minjiang, Ji, Jiansong. 2024. Tumor cell-intrinsic MELK enhanced CCL2-dependent immunosuppression to exacerbate hepatocarcinogenesis and confer resistance of HCC to radiotherapy. In Molecular cancer, 23, 137. doi:10.1186/s12943-024-02049-0. https://pubmed.ncbi.nlm.nih.gov/38970074/
4. Ren, Ling, Guo, Jing-Si, Li, Yu-Heng, Dong, Gang, Li, Xin-Yang. 2022. Structural classification of MELK inhibitors and prospects for the treatment of tumor resistance: A review. In Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 156, 113965. doi:10.1016/j.biopha.2022.113965. https://pubmed.ncbi.nlm.nih.gov/36411642/
5. Yang, Haiyan, Zhou, Huandi, Wang, Guohui, Zhang, Yufeng, Xue, Xiaoying. 2022. MELK is a prognostic biomarker and correlated with immune infiltration in glioma. In Frontiers in neurology, 13, 977180. doi:10.3389/fneur.2022.977180. https://pubmed.ncbi.nlm.nih.gov/36353126/
6. Yu, Hui, Xu, Xianrong, Zhu, Lirong, Chen, Shengjie, He, Jincheng. . MELK aggravates lung adenocarcinoma by regulating EZH2 ubiquitination and H3K27me3 histone methylation of LATS2. In Journal of cellular and molecular medicine, 28, e18216. doi:10.1111/jcmm.18216. https://pubmed.ncbi.nlm.nih.gov/38652219/
智鼠故事 
